Get the latest news, insights, and market updates on CNTA (Centessa Pharmaceuticals plc). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
Nxera Pharma to Receive US$3 Million Milestone Payment from Centessa Pharmaceuticals
Tokyo, Japan and Cambridge, UK, 5 March 2026 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today announces that Centessa Pharmaceuticals has achieved an additional early development milestone associated with its investigational, orally administered, highly potent and selective orexin receptor 2 (OX2R) agonist, ORX489, being developed by Centessa for the treatment of neuropsychiatric disorders. This milestone triggers a payment of US$3 million to Nxera pursuant to its research col Mar 5, 2026 - $CNTA
Why Centessa Pharmaceuticals (CNTA) Is Up 9.6% After Positive ORX750 Phase 2a Sleep-Disorder Data
In recent days, Centessa Pharmaceuticals has drawn attention after reporting positive Phase 2a progress for its lead orexin receptor agonist ORX750 in narcolepsy and idiopathic hypersomnia, alongside updates on its broader neurology and neuropsychiatry pipeline. This momentum has been reinforced by broad analyst support and optimism around Centessa’s early-stage portfolio, even though it still has no approved products. Next, we’ll examine how enthusiasm around ORX750’s Phase 2a results and... Feb 28, 2026 - $CNTA
Orexin-2 Receptor Data Reinforces a Positive Outlook for Centessa (CNTA)
Centessa Pharmaceuticals (NASDAQ:CNTA) is one of the 17 biotechnology stocks with more than 50% upside. On January 29, Danielle Brill from Truist Financial raised her price target on Centessa Pharmaceuticals (NASDAQ:CNTA) from $33 to $38 and assigned a Buy rating to the stock. Her rating came after Truist Financial updated its projections following a thorough […] Feb 16, 2026 - $CNTA
Centessa Pharmaceuticals (CNTA) Valuation Check After Recent Share Price Strength
Centessa Pharmaceuticals: Stock context and recent performance snapshot Centessa Pharmaceuticals (NasdaqGS:CNTA) has attracted attention after recent trading, with the stock last closing at $24.71. For investors, the key question is how this price lines up with its recent performance and fundamentals. See our latest analysis for Centessa Pharmaceuticals. Recent trading has been relatively supportive for sentiment, with a 1 month share price return of 11.86% and a 7 day gain of 5.19%, even... Feb 14, 2026 - $CNTA
Centessa Pharmaceuticals CEO Teases “Transformational” 2026 as ORX750 Nears Registrational Trials
Centessa Pharmaceuticals (NASDAQ:CNTA) CEO Mario Alberto Accardi told attendees at Guggenheim’s 2026 Emerging Outlook Biotech Summit that 2026 is “shaping up to be a transformational year” for the company as it moves its lead orexin agonist program toward registrational studies in rare hypersomnias Feb 13, 2026 - $CNTA
Nxera Pharma to Receive $1.8 Million Milestone Payment from Centessa Pharmaceuticals
Tokyo, Japan and Cambridge, UK, 12 February 2026 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today notes that Centessa Pharmaceuticals has achieved an early development milestone associated with its investigational, orally administered, highly potent and selective orexin receptor 2 (OX2R) agonist, ORX489, being developed by Centessa for the treatment of neuropsychiatric disorders. This milestone triggers a payment of US$1.8 million to Nxera pursuant to its research collaboratio Feb 12, 2026 - $CNTA
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
BOSTON and LONDON, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop transformational medicines for patients, today announced that members of its management team will participate in the following investor conferences: Event: Guggenheim Emerging Outlook: Biotech SummitDate: Thursday, February 12, 2026Fireside Chat: 1:00 PM ET Event: TD Cowen 46th Annual Health Care ConferenceDate: Tuesday, March Feb 3, 2026 - $CNTA
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" to help us understand site usage and improve the platform.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple